The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesWB: 1/500 - 1/5000. Predicted molecular weight: 58 kDa. This antibody was tested using a 15kDA human IFNAR2 recombinant fragment only.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionAssociates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.
Tissue specificityIsoform 3 is detected in the urine (at protein level). Expressed in blood cells. Expressed in lymphoblastoid and fibrosarcoma cell lines.
Sequence similaritiesBelongs to the type II cytokine receptor family.
Post-translational modificationsPhosphorylated on tyrosine residues upon interferon binding. Phosphorylation at Tyr-337 or Tyr-512 are sufficient to mediate interferon dependent activation of STAT1, STAT2 and STAT3 leading to antiproliferative effects on many different cell types. Glycosylated.